L-α甘醇胆使用与延迟痴呆转化之间的关联:韩国一项全国纵向研究
Han-Kyeol Kim1, Sojeong Park2, Sung-Woo Kim3
1Department of Neurology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, South Korea.
The journal of prevention of Alzheimer's disease
|March 28, 2025
概括
补充L-α甘醇胆显著降低了患阿尔茨海默氏症的风险.
科学领域:
- 神经学和老年医学的医学.
- 对认知衰退的药理干预
背景情况:
- 阿尔茨海默病 (AD) 和血管痴呆症 (VaD) 是导致认知障碍的主要原因.
- 对于轻度认知障碍 (MCI) 阶段存在有限的有效治疗方法.
- 早期干预对于管理痴呆症进展至关重要.
研究的目的:
- 评估L-α甘醇胆 (GPC) 在患有MCI的患者的实际有效性.
- 评估GPC对AD痴呆症和VaD转化风险的影响.
- 调查GPC对MCI患者中风风险的影响.
主要方法:
- 全国基于人口的队列研究,利用韩国国家医疗保险服务数据.
- 包括508,107名新诊断患有MCI的患者 (2013-2016).
- 用时间依赖的考克斯回归分析比较L-α GPC用户与非用户.
主要成果:
- L-α GPC使用者显示,AD痴呆症 (HR=0.899) 和VaD (HR=0.832) 的进展风险降低.
- 在65岁以下的患者中,观察到这两种痴呆症的显著风险降低.
- 在没有进展的患者中,中风风险显著降低,但在那些进展为痴呆症的患者中没有降低.
结论:
- L-α GPC显示出作为早期干预措施的潜力,以减少MCI患者的痴呆转化和中风风险.
- 这些发现支持L-α GPC在缓解认知衰退和相关血管事件方面的作用.
- 建议进行进一步的大规模随机对照试验,以探索对其他痴呆症亚型和长期结果的影响.
相关概念视频
01:30Dementia
663
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
663
01:26Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K